Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18998097 | 0.76 | MEN1 (0.63) | HTR7GAAKMT2AMEN1RXFP1 | |
| SCHEMBL23474916 | 0.75 | GAA (0.38) | HTR7GAAKMT2AMEN1KDM4E | |
| SCHEMBL23474997 | 0.75 | GAA (0.38) | HTR7GAAKMT2AMEN1KDM4E | |
| SCHEMBL23475005 | 0.75 | GAA (0.38) | HTR7GAAKMT2AMEN1KDM4E | |
| SCHEMBL12486958 | 0.74 | LTA4H (0.58) | LTA4HKDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL2300940 | 0.74 | LTA4H (0.53) | LTA4HKDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL3154476 | 0.72 | HRH3 (0.57) | LTA4HKDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL21695104 | 0.70 | HRH3 (0.57) | GAAKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL7753956 | 0.69 | MAP4K4 (0.44) | HTR7GAAKMT2AMEN1NPC1 | |
| SCHEMBL1893679 | 0.69 | GAA (0.46) | GAAKMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7132551-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-11-07 | — | — | US | disclosed |
| WO-2005077463-A2 | LIGAND FOR A MONOAMINE RECEPTOR OR TRANSPORTER FOR TREATING ADDICTION OR DEPENDENCE | SEPRACOR INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | SEPRACOR, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | AQUILA BRIAN M (US) | 2004-04-22 | — | — | US | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | PNMT, TAAR1, OPRL1 | HTR7 268/4885GAA 1412/4885KMT2A 393/4885 |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | HTR7 23/4885GAA 238/4885KMT2A 2763/4885 |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | HTR7 23/4885GAA 238/4885KMT2A 2763/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | HTR7 23/4885GAA 238/4885KMT2A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.